Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Salarius Update

15 Nov 2021 07:00

RNS Number : 2949S
Tekcapital plc
15 November 2021
 

15 November 2021

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

 

Portfolio Company Update: Salarius, Ltd. ("Salarius")

AWARDED MOST INNOVATIVE SODIUM REDUCTION FOOD TECHNOLOGY PRIVIDER IN 2021

 

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products from investing in university technology that can improve people's lives, is very pleased to announce that MicroSalt® has been awarded the most innovative sodium reduction food technology provider in 2021 by GHP Magazine, in their annual competition of Fitness and Nutrition Awards. Click here to view award recipients, MicroSalt is listed on page 17.

 

"We are very excited to receive this award from Global Health and Pharma magazine for having the most innovative low sodium product in 2021. MicroSalt's goal is to provide a better salt, that tastes great and reduces excess sodium consumption, a major risk factor for developing cardiovascular disease," said Victor Hugo Manzanilla, CEO of MicroSalt®. 

 

MicroSalt® aims to revolutionize the food industry with its patented sodium microparticle, that delivers the full-flavour experience of salt with roughly half the sodium. MicroSalt®'s salt particles are approximately 100 times smaller than regular table salt, allowing them to rapidly dissolve, producing a large sensation of saltiness. MicroSalt® is all-natural, non-GMO, and Kosher.

 

About Salarius Ltd.

Salarius, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples' lives with better-for-you snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

 

To learn more about MicroSalt please visit https://Salarius.co/. 

To learn more about SaltMe! snacks please visit https://saltme.com/.

 

Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.

 

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

For further information, please contact:

Tekcapital Plc 

Via Flagstaff IR

Clifford M. Gross, Ph.D. 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison / Charlie Bouverat (Corporate Finance)

Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Salarius that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Salarius' and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Salarius or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Salarius nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXFAFFDFFFA
Date   Source Headline
27th May 20267:00 amRNSResults for Year Ended 31 December 2025
22nd May 20267:00 amRNSTekcapital takes stake in geothermal AI firm
21st May 20267:00 amRNSNew Orders
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
18th Feb 20267:00 amRNSNotification of Major Holdings
10th Feb 20267:00 amRNSConditional Placing of £1.5 million
15th Jan 20267:00 amRNSCorporate Update
7th Jan 20267:00 amRNS-RPorfolio Company Update - Innovative Eyewear Inc
12th Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
1st Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
19th Nov 20257:00 amRNSPortfolio Company Update - Guident Corp
13th Nov 20257:00 amRNSInnovative Eyewear Q3 Unaudited Financial Results
13th Nov 20257:00 amRNSTrading Statement
10th Nov 20257:00 amRNS-RStrategic Alliance signed with Nexscient Inc
4th Nov 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
17th Oct 20254:15 pmRNSNotification of Major Holdings
13th Oct 20251:44 pmRNSPlacing of £0.37 Million
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
8th Oct 202510:53 amRNSReplacement - Unaudited Half-Yearly Report
7th Oct 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNS-RPortfolio Company Update -Guident
24th Sep 20257:00 amRNSUnaudited Half Yearly Report
18th Sep 20257:00 amRNSPortfolio Company Update -Guident Proposed US IPO
10th Sep 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
29th Aug 20257:00 amRNS-RPortfolio Company Update Guident Corp
19th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
15th Aug 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear Q2
13th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
6th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
25th Jul 20257:00 amRNSTrading Statement
24th Jul 20257:00 amRNS-RPortfolio Company Update - Guident Corp
21st Jul 20257:00 amRNS-RPortfolio Company Update- Innovative Eyewear
27th Jun 202512:39 pmRNSResult of AGM
19th Jun 20251:06 pmRNSNotification of Major Holdings
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
19th Jun 20257:00 amRNS-RPortfolio Company Update - Guident Corp
10th Jun 20257:00 amRNSContract Win
2nd Jun 20257:02 amRNSNotice of AGM
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
2nd Jun 20257:00 amRNSFundraising of £1.25 Million
29th May 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
23rd May 20257:00 amRNSFinal Results Year Ended 31 December 2024
16th May 20257:00 amRNS-RPortfolio Company Update - Guident Corp
12th May 20257:00 amRNSPortfolio Company Update:Guident Corp Proposed IPO
6th May 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc.
28th Apr 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc
24th Apr 20257:00 amRNSQ1 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.